Cobblestone Capital Advisors LLC NY Decreases Position in AstraZeneca PLC $AZN

Cobblestone Capital Advisors LLC NY cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 48.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 3,174 shares of the company’s stock after selling 3,000 shares during the quarter. Cobblestone Capital Advisors LLC NY’s holdings in AstraZeneca were worth $222,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AZN. Goldman Sachs Group Inc. raised its stake in AstraZeneca by 30.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after acquiring an additional 3,224,251 shares during the last quarter. Valeo Financial Advisors LLC raised its stake in shares of AstraZeneca by 14,797.3% in the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after purchasing an additional 2,307,047 shares during the last quarter. American Century Companies Inc. raised its stake in shares of AstraZeneca by 406.9% during the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after buying an additional 1,621,974 shares during the last quarter. Boston Partners raised its stake in shares of AstraZeneca by 35.9% during the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock valued at $368,712,000 after buying an additional 1,329,166 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of AstraZeneca by 650.1% during the 1st quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock valued at $90,761,000 after buying an additional 1,070,223 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 0.9%

Shares of AZN opened at $84.06 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $86.57. The firm has a 50-day moving average price of $80.97 and a 200 day moving average price of $74.58. The firm has a market capitalization of $260.70 billion, a P/E ratio of 31.60, a P/E/G ratio of 1.54 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.24 earnings per share. Sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on AZN. Jefferies Financial Group started coverage on shares of AstraZeneca in a report on Monday. They set a “buy” rating for the company. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.